Sumecigrel
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Sumecigrel
- Molecular weight
- 379.87
- Structure (SMILES)
- COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc(OC(C)=O)cc2C1
- (S)-2-(2-Acetoxy-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorophenyl)acetic acid methyl ester
- s 2 2 acetoxy 6 7 dihydrothieno 3 2 c pyridine 5 4h yl 2 2 chlorophenyl acetic acid methyl ester
- sumecigrel
- Sumecigrel
- sumecigrel [INN]
- SUMECIGREL [USAN]
- sumecigrel inn
- sumecigrel usan
- vicagrel
- Vicagrel
- vicagrel 5mg
- Vicagrel 5mg
- vicagrel 6mg
- Vicagrel 6mg
- vicagrel 7 5mg
- Vicagrel 7.5mg
- vicagrel capsules
- vicagrel Capsules
- Vicagrel Capsules
- CAS registry numbers
- 1314081-53-2
- ChEMBL ID
- CHEMBL2042273
- InChIKey
- GNHHCBSBCDGWND-KRWDZBQOSA-N
- PubChem compound IDs
- 53378151
- FDA ingredient codes (UNII)
- 8A63K3TN0U
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -grel
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition
- Blood Platelet Disorders
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002245
- Subject identifier
- D001791
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0005672
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002245
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005542
- Highest recorded phase
- 3
- NCT04919551
- NCT05162053
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 55.84
- Calculated partition coefficient (ALogP)
- 3.6
- Calculated partition coefficient (XLogP)
- 3.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 25
- Molecular formula
- C18H18ClNO4S
- Monoisotopic mass
- 379.0645069
- Natural product
- No
- Recorded assays
- 15
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (8)
- A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects
- Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects
- Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
- Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19
- PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers
- The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
- The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man
In development for (3)
- Acute coronary syndrome Phase 1
- Blood platelet disease Phase 1
- Neoplasm Phase 2